SAFETY ASSESSMENT CONSIDERATIONS FOR ANTIBODY DRUG CONJUGATES

被引：0
|
作者：
Hinkle, Beth [1 ]
机构：
[1] Amgen Inc, Thousand Oaks, CA USA
来源：
DRUG METABOLISM REVIEWS | 2012年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：23 / 24
页数：2
相关论文
共 50 条
  • [21] Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs)
    Hoffmann, Ricarda M.
    Coumbe, Ben G. T.
    Josephs, Debra H.
    Mele, Silvia
    Ilieva, Kristina M.
    Cheung, Anthony
    Tutt, Andrew N.
    Spicer, James F.
    Thurston, David E.
    Crescioli, Silvia
    Karagiannis, Sophia N.
    ONCOIMMUNOLOGY, 2018, 7 (03):
  • [22] Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer
    Malik, Paul
    Phipps, Colin
    Edginton, Andrea
    Blay, Jonathan
    PHARMACEUTICAL RESEARCH, 2017, 34 (12) : 2579 - 2595
  • [23] Pharmacokinetics and toxicity considerations for antibody-drug conjugates: an overview
    Hejmady, Siddhanth
    Pradhan, Rajesh
    Kumari, Shobha
    Pandey, Meghna
    Dubey, Sunil K.
    Taliyan, Rajeev
    BIOANALYSIS, 2023, 15 (19) : 1193 - 1202
  • [24] Safety and Tolerability of Antibody-Drug Conjugates in Cancer
    Anna Wolska-Washer
    Tadeusz Robak
    Drug Safety, 2019, 42 : 295 - 314
  • [25] Immunogenicity considerations for antibody-drug conjugates: a focus on neutralizing antibody assays
    Fiorotti, Corinna K.
    BIOANALYSIS, 2018, 10 (02) : 65 - 70
  • [26] Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer
    Paul Malik
    Colin Phipps
    Andrea Edginton
    Jonathan Blay
    Pharmaceutical Research, 2017, 34 : 2579 - 2595
  • [27] Safety and Tolerability of Antibody-Drug Conjugates in Cancer
    Wolska-Washer, Anna
    Robak, Tadeusz
    DRUG SAFETY, 2019, 42 (02) : 295 - 314
  • [28] Optimizing the safety of antibody–drug conjugates for patients with solid tumours
    Paolo Tarantino
    Biagio Ricciuti
    Shan M. Pradhan
    Sara M. Tolaney
    Nature Reviews Clinical Oncology, 2023, 20 : 558 - 576
  • [29] ADME and DMPK considerations for the discovery and development of antibody drug conjugates (ADCs)
    Beaumont, Kevin
    Pike, Andy
    Davies, Michael
    Savoca, Adriana
    Vasalou, Christina
    Harlfinger, Steffi
    Ramsden, Diane
    Ferguson, Douglas
    Hariparsad, Niresh
    Jones, Owen
    McGinnity, Dermot
    XENOBIOTICA, 2022, 52 (08) : 770 - 785
  • [30] Biosimilar antibody drug conjugates: considerations of higher order structure and aggregation
    Easton, Richard L.
    GABI JOURNAL-GENERICS AND BIOSIMILARS INITIATIVE JOURNAL, 2023, 12 (03):
12345